Current SARS-CoV-2 activity remains low globally with stable, moderate risk per WHO assessments through mid-2026, reflecting endemic circulation rather than pandemic emergence. Ongoing genomic surveillance tracks variants like BA32 for immune escape traits, yet none have driven exponential growth or overwhelmed systems, consistent with CDC modeling projecting limited summer increases absent major changes. A newly sequenced betacoronavirus in Brazilian bats shares some features with SARS-CoV-2 but shows no confirmed human transmission risk. Trader consensus at 96% for no new pandemic aligns with this surveillance data and absence of novel spillovers meeting WHO criteria. Realistic shifts could still arise from undetected zoonotic events or rapid evolution of a highly transmissible, immune-evasive strain before year-end.